Mutational spectrum
More than 200 Dent-1 disease patients with CLCN5 defects have been described, with disease-causing mutations scattered throughout the gene. [1] [2] [3] [4] [5] [6] The mutational spectrum includes missense (44%) and nonsense (26%) mutations, small deletions/insertions (15%) and splice defects (11%), with a few hotspots, mainly affecting arginine codons. Large insertions/deletions may be detected in around 4% of the patients. 6 OCRL mutations in Dent-2 disease patients are not uniformly distributed. Missense mutations are mainly found in exons 8-15, nonsense or frameshift mutations almost always affect exons 1-7. 6, 7 Human wild-type ClC-5/OCRL-1 with their corresponding exon numbering are deposited in GenBank, accession nos. NG_007159.2 and NP_000267.2. CLCN5 and OCRL mutations are included in the Human Gene Mutation Database (http://www.hgmd.org/) or can be obtained via the Leiden Open Variation Database (http://grenada. lumc.nl/LOVD2/MR/home.php?select_db=CLCN5 or http://www.ncbi. nlm.nih.gov/lovd/home.php?select_db=OCRL). Novel data should be shared through these databases.
Analytical methods
Bi-directional Sanger sequencing of PCR-amplified products comprising the total coding region and the exon-intron boundaries of the CLCN5 gene and, when negative, the OCRL gene.
Analytical validation
Confirmation of the detected mutation at least from a second amplicon, preferentially from an independent biological sample of the index case. Pathogenicity of novel missense variants has to be verified by (i) testing a set of at least 100 chromosomes from normal ethnically matched controls, (ii) considering its deposition in singlenucleotide polymorphism databases and (iii) using in silico prediction methods. The gold standard is analysis of functional consequences of the respective CLCN5/OCRL mutation in Xenopus laevis oocytes or cell models, performed in a few laboratories in the world. Gene transcripts should be analyzed in case of splice mutations.
1.8 Estimated frequency of the disease (Incidence at birth ('birth prevalence') or population prevalence) To date, around 250 families with Dent-1 disease and about 50 patients with Dent-2 disease have been reported. Based on these data and considering the highly variable presentation, disease frequency cannot be estimated.
1.9 If applicable, prevalence in the ethnic group of investigated person Not applicable.
Diagnostic setting
The clinical presentation of Dent disease is frequently subtle with the majority of patients being asymptomatic in childhood. Many patients are identified through urine screening for hematuria and proteinuria, a current method in Japanese school children. 1, 8 Although nephrocalcinosis and hypercalciuria are characteristic findings in Dent disease, only low-molecular-weight proteinuria is uniformly present in all patients. 9, 10 Additional features observed in patients are aminoaciduria (in 40-50%), phosphate (in 20-25%) and potassium wasting (in 5-15%), glycosuria (in 10-20%), renal tubular acidosis (in 3-5%) and renal failure in adulthood. 9 Manifestations of Dent disease are highly variable, even within the same family, and there is no genotypephenotype correlation. 10 Dent-2 disease is caused by mutations in OCRL, the gene previously identified as the cause of the oculo-cerebro-renal syndrome (Lowe syndrome, OMIM 309000). 11, 12 Patients show a renal phenotype comparable to Dent-1 disease, except for a lower prevalence of nephrocalcinosis. 9 Dent-2 disease may present with additional (mild) extra-renal features of the Lowe syndrome spectrum, for example, peripheral cataracts, mild cognitive and/or mental impairment, stunted growth and elevated serum CK/LDH levels. 9 Prenatal diagnosis is feasible if the familial mutation is known but is of no clinical benefit.
TEST CHARACTERISTICS 2.1 Analytical sensitivity (proportion of positive tests if the genotype is present)
Close to 100%. The sensitivity of sequence analysis of PCR-amplified products approaches 100%. A lot of variants have been tested functionally, [13] [14] [15] [16] and the pathogenicity of most mutants has been predicted by publically available algorithms. Nonetheless, errors may occur due to allele dropout and mutations outside the coding region in the promoter, polyA-site, enhancers or intronic variants may be missed.
Analytical specificity (proportion of negative tests if the genotype is not present)
Nearly 100%. In rare cases, variants may erroneously be interpreted as pathogenic.
Clinical sensitivity (proportion of positive tests if the disease is present)
Mutations in CLCN5 (Dent-1 disease; 60%) and OCRL (Dent-2 disease; 15%) account for 75% of cases with a phenotype of Dent disease. Sensitivity around 75%.
Clinical specificity (proportion of negative tests if the disease is not present)
The clinical specificity can be dependent on variable factors, such as age or family history. In such cases, a general statement should be given, even if a quantification can only be made case by case.
Close to 100%.
Positive clinical predictive value (life-time risk to develop the disease if test is positive)
100%. But considerable variability in symptoms.
Negative clinical predictive value (probability of not developing the disease if the test is negative)
Mutation demonstrated in index case from the family: 100%. Index case in that family not been tested: Consider the X-linked recessive mode of inheritance. If CLCN5 and OCRL are both normal, the negative predictive value is 75%. 
CLINICAL UTILITY

Describe the burden of alternative diagnostic methods to the patient
The diagnosis of Dent disease is based on a high index of clinical suspicion, as the presenting symptoms are non-specific (proteinuria, kidney stones, renal failure).
The biochemical diagnosis of Dent disease is not invasive (spot urine for low-molecular-weight proteinuria, hypercalciuria and variable presence of other proximal tubular dysfunctions). Nephrocalcinosis and kidney stones can usually be demonstrated by abdominal ultrasound. The amount of total protein excretion may be in the nephrotic range, suggesting a glomerular disease. In this situation, genetic testing can avoid a renal biopsy, which is an invasive and potentially dangerous (bleeding) procedure.
Genetic testing may be crucial in patients presenting with end-stage renal disease, as the urine tests are unreliable in this setting (decrease in calcium excretion, non-specific low-molecular-weight proteinuria from tubulo-interstitial damage).
How is the cost effectiveness of alternative diagnostic methods to be judged?
The cost effectiveness of renal ultrasound and biochemical studies is very high.
As low-molecular-weight proteinuria is an obligate finding in Dent disease, this test is of crucial importance and can replace genetic testing in siblings of a genetically proven index case. In this situation, urine biochemistry is much more cost-effective than genetic testing. The presence of other biochemical findings in Dent disease is variable.
Will disease management be influenced by the result of a genetic test?
Yes. In cases with nephrotic range proteinuria, who might undergo a renal biopsy or receive immunosuppressive therapy. 17 
Predictive
IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING
Please assume that the result of a genetic test has no immediate medical consequences. Is there any evidence that a genetic test is nevertheless useful for a patient or his/her relatives?
Follow-up is warranted in patients with Dent disease. Potential medical interventions include high fluid intake, thiazide diuretics 18 and potassium citrate supplementation. 19 Animal studies suggest a positive effect of citrate suppletion in a Clcn5 knockout mouse model (on kidney function and calcium deposits). 19 Human data have documented a decrease in hypercalciuria with thiazide diuretics, 18 yet at the expense of hypokalemia in some patients. The long-term efficacy on the progression of renal failure has not been studied, however.
